Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

Exclusion Criteria

• •Patients with HER2(-) status
• •Patients who have tumor deposit(s) that are easily accessible by ultrasound or CT guidance
• •Patients must have adequate organ function
• •Patients must provide written informed consent
• •Active concurrent malignancy, other than superficial, non-squamous cell carcinoma of the skin or uterine cervix, within the past three years
• •ECOG performance status worse than 2
• •Prior oral or intravenous chemotherapy for metastatic disease
• •Patients with comorbidities that prevent them from being able to receive the chemotherapy regimen
• •cardiac ejection fraction 45% or greater